BioCryst Pharmaceuticals, Inc.
BCRX
$9.81
$0.657.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 94.10% | 45.38% | 45.85% | 41.67% | 36.00% |
| Total Other Revenue | -- | -10.63% | -4.70% | 2.30% | 140.72% |
| Total Revenue | 94.10% | 45.38% | 45.85% | 41.67% | 36.00% |
| Cost of Revenue | -2.57% | -4.71% | -7.70% | -16.41% | -14.28% |
| Gross Profit | 161.85% | 91.82% | 106.00% | 130.70% | 130.92% |
| SG&A Expenses | 30.16% | 33.39% | 33.97% | 28.47% | 24.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.71% | 16.53% | 14.72% | 6.54% | 5.07% |
| Operating Income | 27,254.26% | 316.23% | 200.13% | 140.58% | 98.71% |
| Income Before Tax | 407.51% | 94.67% | 78.02% | 75.46% | 61.56% |
| Income Tax Expenses | 83.19% | 801.95% | 723.58% | 57,100.00% | 521.61% |
| Earnings from Continuing Operations | 396.87% | 92.91% | 75.53% | 74.37% | 60.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 396.87% | 92.91% | 75.53% | 74.37% | 60.77% |
| EBIT | 27,254.26% | 316.23% | 200.13% | 140.58% | 98.71% |
| EBITDA | 1,056,742.42% | 336.90% | 207.65% | 143.50% | 99.97% |
| EPS Basic | 390.91% | 92.87% | 76.38% | 75.80% | 63.50% |
| Normalized Basic EPS | 432.79% | 101.04% | 81.71% | 72.87% | 58.45% |
| EPS Diluted | 378.68% | 91.85% | 75.42% | 75.59% | 63.35% |
| Normalized Diluted EPS | 420.02% | 100.08% | 81.35% | 72.85% | 58.45% |
| Average Basic Shares Outstanding | 1.54% | 1.85% | 3.63% | 5.51% | 7.56% |
| Average Diluted Shares Outstanding | 5.75% | 5.07% | 5.71% | 6.33% | 7.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |